What’s New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.

In addition to updates to all the sections, the following new sections have been added to the guidance:

Related Posts

Research

Perceived benefits of the hepatitis C peer educators: a qualitative investigation

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-017-0192-8 New article from the Harm reduction journal about improving HCV treatment successes.

Coalition Activity

October 23 – Comprehensive User Engagement Sites – A Multidisciplinary Educational Session

Monday, October 23, 2017 6PM-8PM Broad Street Ministries 315 South Broad Street Philadelphia PA

Coalition Activity

October 26th – Join Harm Reduction Coalition and PRIME Education, LLC for a live webinar titled HCV Testing & Linkage to Care Through the Lens of Substance Use Disorder Clinics.

Register Here Thursday, October 26th, 2017 at 2PM EST This unique webinar highlights key findings from a recent educational series to train counselors, clinicians, and other healthcare providers working in substance use disorder clinics to Read more…